Suppr超能文献

CYP3A4 和 CYP3A5 的差异调节及其在药物发现中的意义。

Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.

机构信息

Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

Integrated Biomedical Sciences Program, University of Tennessee Health Science Center, Memphis, TN, USA.

出版信息

Curr Drug Metab. 2017;18(12):1095-1105. doi: 10.2174/1389200218666170531112038.

Abstract

BACKGROUND

Cancer cells use several mechanisms to resist the cytotoxic effects of drugs, resulting in tumor progression and invasion. One such mechanism capitalizes on the body's natural defense against xenobiotics by increasing the rate of xenobiotic efflux and metabolic inactivation. Xenobiotic metabolism typically involves conversion of parent molecules to more soluble and easily excreted derivatives in reactions catalyzed by Phase I and Phase II drug metabolizing enzymes.

METHODS

We performed a structured search of peer-reviewed literature on P450 (CYP) 3A, with a focus on CYP3A4 and CYP3A5.

RESULTS

Recent reports indicate that components of the xenobiotic response system are upregulated in some diseases, including many cancers. Such components include the pregnane X receptor (PXR), CYP3A4 and CYP3A5 enzymes. The CYP3A enzymes are a subset of the numerous enzymes that are transcriptionally activated following the interaction of PXR and many ligands.

CONCLUSION

Intense research is ongoing to understand the functional ramifications of aberrant expression of these components in diseased states with the goal of designing novel drugs that can selectively target them.

摘要

背景

癌细胞利用多种机制来抵抗药物的细胞毒性作用,导致肿瘤的进展和侵袭。其中一种机制是利用机体对异源生物的天然防御机制,增加异源生物的外排和代谢失活速度。异源生物代谢通常涉及母体分子在Ⅰ相和Ⅱ相药物代谢酶的催化下转化为更具水溶性和易排泄的衍生物。

方法

我们对 P450(CYP)3A 的同行评议文献进行了结构化检索,重点是 CYP3A4 和 CYP3A5。

结果

最近的报告表明,异源生物反应系统的一些成分在包括许多癌症在内的一些疾病中上调。这些成分包括孕烷 X 受体(PXR)、CYP3A4 和 CYP3A5 酶。CYP3A 酶是 PXR 与许多配体相互作用后转录激活的众多酶中的一个子集。

结论

目前正在进行大量研究,以了解这些成分在疾病状态下异常表达的功能后果,目的是设计能够选择性靶向这些成分的新型药物。

相似文献

1
Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.
Curr Drug Metab. 2017;18(12):1095-1105. doi: 10.2174/1389200218666170531112038.
2
Statin regulation of CYP3A4 and CYP3A5 expression.
Pharmacogenomics. 2009 Jun;10(6):1017-24. doi: 10.2217/pgs.09.42.
5
Overexpression of CYP3A5 attenuates inducibility and activity of CYP3A4 in HepG2 cells.
Mol Med Rep. 2015 Apr;11(4):2868-74. doi: 10.3892/mmr.2014.3022. Epub 2014 Dec 1.
8
Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor.
Cancer Chemother Pharmacol. 2009 Jun;64(1):35-43. doi: 10.1007/s00280-008-0842-3. Epub 2008 Oct 7.
9
Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance.
Chem Biol Interact. 2021 May 1;340:109448. doi: 10.1016/j.cbi.2021.109448. Epub 2021 Mar 26.

引用本文的文献

1
Evolutionary Transcriptomics of Cancer Development.
Int J Mol Sci. 2025 May 23;26(11):5041. doi: 10.3390/ijms26115041.
2
Effects of mallotus furetianus extract on CYP3A activities in rats.
Sci Rep. 2025 May 27;15(1):18530. doi: 10.1038/s41598-025-02193-7.
3
Bioinformatics-driven exploration of key genes and mechanisms underlying oxidative stress in traumatic brain injury.
Front Aging Neurosci. 2025 Apr 25;17:1531317. doi: 10.3389/fnagi.2025.1531317. eCollection 2025.
5
Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B).
Contemp Clin Trials Commun. 2025 Mar 29;45:101477. doi: 10.1016/j.conctc.2025.101477. eCollection 2025 Jun.
6
Polymorphism in Circulating Tumor Cells Confers an Increased Disease-Free Survival in DLBCL Patients Treated with R-CHOP.
Onco Targets Ther. 2025 Mar 14;18:355-366. doi: 10.2147/OTT.S486400. eCollection 2025.
7
Integrated Pharmacogenetic Signature for the Prediction of Prostatic Neoplasms in Men With Metabolic Disorders.
Cancer Genomics Proteomics. 2025 Mar-Apr;22(2):285-305. doi: 10.21873/cgp.20502.
9
Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer.
Cell Chem Biol. 2024 Dec 19;31(12):2069-2084.e9. doi: 10.1016/j.chembiol.2024.09.004. Epub 2024 Oct 7.

本文引用的文献

1
Glucocorticoid receptor control of transcription: precision and plasticity via allostery.
Nat Rev Mol Cell Biol. 2017 Mar;18(3):159-174. doi: 10.1038/nrm.2016.152. Epub 2017 Jan 5.
2
Suppression of cytochrome P450 4B1: An early event in adrenocortical tumorigenesis.
Surgery. 2017 Jan;161(1):257-263. doi: 10.1016/j.surg.2016.04.056. Epub 2016 Nov 16.
3
Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism.
PLoS One. 2016 Oct 27;11(10):e0165631. doi: 10.1371/journal.pone.0165631. eCollection 2016.
4
Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor.
J Steroid Biochem Mol Biol. 2016 Oct;163:77-87. doi: 10.1016/j.jsbmb.2016.04.006. Epub 2016 Apr 20.
5
DNA Methylation of ADME Genes.
Clin Pharmacol Ther. 2016 May;99(5):512-27. doi: 10.1002/cpt.343. Epub 2016 Feb 19.
6
Effects of CYP3A5 genetic polymorphism and smoking on the prognosis of non-small-cell lung cancer.
Onco Targets Ther. 2016 Mar 14;9:1461-9. doi: 10.2147/OTT.S94144. eCollection 2016.
7
Small-molecule modulators of PXR and CAR.
Biochim Biophys Acta. 2016 Sep;1859(9):1141-1154. doi: 10.1016/j.bbagrm.2016.02.013. Epub 2016 Feb 24.
10
Variability in Expression of CYP3A5 in Human Fetal Liver.
Drug Metab Dispos. 2015 Aug;43(8):1286-93. doi: 10.1124/dmd.115.064998. Epub 2015 May 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验